GNOMX was founded to commercialize host response epigenetic diagnostics based on research funded by a $46 million DARPA ECHO contract to an academic consortium led by the Icahn School of Medicine at Mount Sinai, Yale University School of Medicine, Princeton University, and the University of Pittsburgh School of Medicine. The DARPA-sponsored research developed patent-pending, beyond state-of-the-art blood epigenetic tests that rapidly diagnose, determine time of exposure, and monitor long-term effect of infections and other exposures.
Company Details
- Employees
- 2
- Founded
- 2022
- Address
- New York, Ny 10128, Us
- Industry
- Medical And Diagnostic Laboratories
- NAICS
-
Medical and Diagnostic LaboratoriesMedical LaboratoriesDiagnostic Imaging Centers
- Website
- http://www.gnomx.com
- HQ
- New York, NY
Gnomx Corp. Questions
Gnomx Corp.'s website is http://www.gnomx.com
Gnomx Corp.'s LinkedIn profile is https://www.linkedin.com/company/gnomx-corp
Gnomx Corp. has
2 employees.
View email and phone details for 2
employees at Gnomx Corp..
Gnomx Corp.'s industry is
Medical and Diagnostic Laboratories
Gnomx Corp.'s top competitors are
Dna Medicine Institute,
Rizlab Health, Inc.,
Cirrusdx, Inc.,
Assurance Health Data,
Patchd Medical (Now Sepsis Scout),
Stoutland Enterprises,
Pheal,
Immunexpress Inc.,
Proactive Diagnostics,
Veteran Success Resource Group (Vsrg).
Gnomx Corp.'s categories are Medical and Diagnostic Laboratories
Gnomx Corp.'s founding year is 2022
